RNS Number : 2516O
Futura Medical PLC
02 December 2024
 

2 December 2024

Futura Medical PLC

Block Listing Six Monthly Return

Futura Medical plc (AIM: FUM), a developer of innovative sexual health products, including lead product Eroxon, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).

Date: 2 December 2024

Name of applicant:

Futura Medical Plc

Name of scheme(s):

Unapproved Share Option Scheme

Unapproved Share Incentive Scheme

EMI Share Option Scheme

LTIP Scheme

Period of return:

From:

1 June 2024

To:

30 November 2024

Balance of unallotted securities under scheme(s) from previous return:

20,782,665

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

USOS: nil

USIS: nil

EMI: nil

LTIP: nil

Less:  Number of securities issued/allotted under scheme(s) during period:

USOS: 250,000

USIS: nil

EMI: 250,000

LTIP: 1,754,120

 

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

18,528,545

Number and class of securities originally admitted and the date of admission

USOS Total: 3,882,912

814,424 25 May 2011

1,202,280             8 October 2013

1,466,208             25 May 2017

400,000 30 May 2018

 

USIS Total: 425,000

425,000 30 November 2018

 

EMI Total: 8,112,088

1,520,576             25 May 2011

1,467,720             8 October 2013

1,893,792             25 May 2017

790,000 30 May 2018

1,340,000             30 November 2018

1,100,000           2 February 2023

 

LTIP Total:  15,035,617

4,444,942            2 February 2023

10,590,675          3 November 2023

 

Contacts:

Futura Medical plc

 

 

 

James Barder

Chief Executive Officer

Angela Hildreth

Finance Director and COO

 

investor.relations@futuramedical.com

+44 (0)1483 685 670

www.futuramedical.com

 

Panmure Liberum

Nominated Adviser

and Broker

 

Emma Earl, Will Goode, Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

+44 (0)20 3100 2000

 

 

 



Stifel Nicolaus Europe Limited

Joint Broker

 

Alan Selby

Ben Maddison

 

+44 (0)207 710 7600

 

 

 



Alma Strategic Communications

Rebecca Sanders-Hewett

Sam Modlin

Will Ellis Hancock

+44 (0)20 3405 0205

futura@almastrategic.com




 

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.

ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRBLBFTMTITBTI
Futura Medical (LSE:FUM)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Futura Medical Charts.
Futura Medical (LSE:FUM)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Futura Medical Charts.